samedan logo
 
 
spacer
home > ict > autumn 2017 > perfect planning
PUBLICATIONS
International Clinical Trials

Perfect Planning

The cell and gene therapies being developed today have the potential to cure diseases. To make those treatments possible, another industry has to evolve: logistics. In the past two decades, gene-based clinical trials have increased by almost 500%. The global market for regenerative medicines – including cell therapies, gene/gene-modified cell therapy and tissue engineering – is poised to reach $67 billion in 2020.

While the majority of cell and gene therapies are still experimental – aimed at rare single-gene disorders – researchers hope to build on their successes to develop treatments for multi-gene disorders, including heart disease, hypertension, diabetes, arthritis and Alzheimer’s. This makes the success of clinical trials now vitally important to humanity. However, therein lies the challenge. Unlike traditional medicines, these therapies contain living cells or viral vectors that must be protected to ensure their survival and effectiveness.

Therapies that contain these materials are produced and packaged under strictly controlled conditions. They must be transported around the world and delivered on time at optimum temperature to ensure they arrive in perfect condition. This must be done regardless of weather, traffic, mechanical difficulties, staffing irregularities, customs regulations or processing delays.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Lisa Vocat is Global Content Marketing Manager at World Courier, part of AmerisourceBergen’s global specialty logistics business. She is responsible for World Courier’s content marketing strategy and thought leadership development.
spacer
Lisa Vocat
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CHDI Foundation extends collaboration with IRBM to accelerate development of Huntington’s disease therapeutics

IRBM, a global contract research organization (CRO), has strengthened its position in neurodegenerative disease research following an extension of its long-standing collaboration with CHDI Foundation, a nonprofit biomedical research organization exclusively dedicated to collaboratively developing therapeutics that substantially improve the lives of those affected by Huntington’s disease (HD).
More info >>

White Papers

Future-proofing serialization solutions: the importance of strong level 3 capabilities

Adents

The complexities surrounding product serialization for pharmaceutical and medical device companies are immense. While current serialization requirements are limited to marking the unit of sale with a unique data carrier, by 2023 the process will require a product to be traceable through the entirety of its journey - from the individual package through the carton/pallet to its final point of distribution. In the United States, the Healthcare Distribution Management Association (HDMA) is suggesting that pharmaceutical companies begin to support this level of serialization, called aggregation, now. Around the world – in Europe and Asia in particular – disparate track and trace practices are incrementally moving toward a global standard that will, undoubtedly, be more stringent than today’s differing benchmarks. How can companies manage this transformation with the greatest degree of success while also minimizing business disruption? The key to creating an optimal implementation strategy is to select a serialization solution that has strong capabilities at all levels of technology. It’s also important to choose a solution that enables multi-phase implementation
More info >>

 
Industry Events

Drug Delivery Partnerships 2019

28-30 January 2019, PGA National Resort & Spa in Palm Beach Gardens, FL

For 23 years, DDP has been the world’s largest drug delivery meeting place to accelerate drugs to market and lengthen lifecycles for long term profitability by finding new partners, new drug delivery technologies, and new formulation development strategies. Year after year this event brings together top scientists and business development leaders from Biotech, Pharma, Generics, Specialty Pharma and Drug Delivery companies to share, discuss, and collaborate. If you work in drug delivery, commercialization/licensing, med device, formulation, biologics, biosimilars, and similar areas, you can’t miss this event!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement